insights_auto
Outlook: 45.0% bullish·0.0% bearish
Go to analysischevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$150.07
arrow_upward
+1.52%(+2.25) 1D
Nov 20, 11:03:06 AM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$148.35
High
$151.40
Low
$148.00
Mkt. cap
20.10B
Avg. vol.
2.71M
Volume
332.13K
P/E ratio
7.60
52-wk high
$479.79
52-wk low
$146.51
EPS
$19.75
Beta
0.42
Shares outstanding
133.94M
No. of employees
2K
Open
$148.35
High
$151.40
Low
$148.00
Mkt. cap
20.10B
Avg. vol.
2.71M
Volume
332.13K
P/E ratio
7.60
52-wk high
$479.79
52-wk low
$146.51
EPS
$19.75
Beta
0.42
Shares outstanding
133.94M
No. of employees
2K
News stories
From web sources and news partners
Yahoo Finance
·
3 hours ago
Alnylam to Webcast Presentations at Upcoming December Investor Conferences
Benzinga
·
3 hours ago
Jim Cramer Rejects UiPath Despite Cheap Valuation, Backs Affirm
Benzinga
·
1 day ago
Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEO-
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitealnylam.com